Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in DermatologyBusiness Wire • 02/19/24
Novo Nordisk Has More Than Ozempic. One of Its Other Treatments Grew 393% Last Year.The Motley Fool • 02/18/24
1 Potential Catalyst That Could Light a Fire Under Novo Nordisk's Stock This YearThe Motley Fool • 02/14/24
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.The Motley Fool • 02/13/24
This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less riskMarket Watch • 02/12/24
Novo Nordisk's controlling shareholder plans to invest up to $7 bln a year by 2030 - FTReuters • 02/12/24
Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change thatCNBC • 02/10/24
